SAN DIEGO, Oct. 29, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of molecular
diagnostic tests and services for physicians treating patients with
cancer, announces an update on its COVID-19 testing with more than
80,000 samples received to date for processing through its RT-PCR
technology at its CLIA-certified, CAP-accredited high-complexity
molecular laboratory.
"We have gained momentum in testing for the COVID-19 virus, with
approximately 30,000 sample received during the past three weeks
alone, and are continually adding more equipment and human
resources to accommodate additional growth and peak daily sample
volume," said Michael Nall,
President and CEO of Biocept. "I'm proud of our team for their
dedication to the fight against the pandemic and continuing to
provide the vast majority of COVID-19 test results to our
healthcare provider customers within 48 hours of receiving a
sample."
"Performing highly accurate RT-PCR testing for COVID-19 will be
an important aspect of our business for the near future as a third
wave of the virus sweeps across the country," he added.
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options.
Additionally, Biocept is offering nationwide COVID-19
polymerase chain reaction (PCR) testing to support public health
efforts during this unprecedented pandemic. For more
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. To the extent that statements in this
release are not strictly historical, including without limitation
statements regarding the growth of demand for our COVID-19 testing
services, our plan and ability to maintain and/or increase our
COVID-19 testing capacity and provide timely results, and the
ability of Biocept's platform to identify cancer mutations and
alterations to inform physicians about a patient's disease and
therapeutic options, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The reader is cautioned
not to put undue reliance on these forward-looking statements, as
these statements are subject to numerous risk factors as set forth
in our Securities and Exchange Commission (SEC) filings. The
effects of such risks and uncertainties could cause actual results
to differ materially from the forward-looking statements contained
in this release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
www.sec.gov.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-provides-update-on-covid-19-testing-with-more-than-80-000-samples-received-301162675.html
SOURCE Biocept, Inc.